New MRI contrast agents show promise

Researchers at AAIC 2020 reported promising findings from preliminary studies of potential new MRI contrast agents for identifying early signs of neurodegeneration.

In one study, researchers performed a dose-ranging efficacy study of ADx-001, an amyloid-targeted liposomal macrocyclic gadolinium (Gd) contrast agent, for in vivo MRI of amyloid plaques in mice. They used a transgenic mouse model of early-onset Alzheimer’s disease, in which amyloid plaques develop from 6-7 months of age, and wide-type amyloid-negative controls.

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.